Main Article Content
The solid-state properties of drug compounds, such as solubility and dissolution, can be changed by
cocrystallizing the drug with coformers. The purpose of the current effort was to identify potential coformers and
then develop, formulate, and assess the lumefantrine cocrystal. Methods: Lumefantrine cocrystals were created
using the solvent evaporation process. The crystalline phase’s melting temperature and solubility were established.
DSC, IR, and XRPD were used to characterize the putative cocrystal. Evaluations were also conducted on
solubility and dissolution rate, two additional medicinal qualities. Results and Discussion: Lumefantrine-adipic
acid cocrystals showed a range in solubility and melting points. Adipic acid and the cocrystals were combined
in a 1:1 ratio. The infrared research clearly showed that the lumefantrine distinctive bands were changing.
A notable variation in the 2θ of the strong peaks and the crystallinity of cocrystals were indicated by the X-ray
powder diffraction pattern. Cocrystal’s differential scanning calorimetry spectra revealed changed melting point
endotherms. Due to cocrystallization, the cocrystals showed a higher rate of dissolution, as seen by an increase
in the extent of dissolution. Conclusion: The lumefantrine cocrystal with modified properties was prepared with
adipic acid having greater solubility and dissolution rate of the drug.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.